Document Detail


HLA-G is a potential tumor marker in malignant ascites.
MedLine Citation:
PMID:  14555519     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Molecular approaches as supplements to cytological examination of malignant ascites may play an important role in the clinical management of cancer patients. HLA-G is a potential tumor-associated marker and that one of its isoforms, HLA-G5, produces a secretory protein. This study is to assess the clinical utility of secreted HLA-G levels in differential diagnosis of malignant ascites. EXPERIMENTAL DESIGN: We used ELISA to assess whether secretory HLA-G (sHLA-G) could serve as a marker of malignant ascites in ovarian and breast carcinomas, which represent the most common malignant tumors causing ascites in women. RESULTS: On the basis of immunohistochemistry, 45 (61%) of 74 ovarian serous carcinomas and 22 (25%) invasive ductal carcinomas of the breast demonstrated HLA-G immunoreactivity ranging from 2 to 100% of the tumor cells. HLA-G staining was not detected in a wide variety of normal tissues, including ovarian surface epithelium and normal breast tissue. Revese transcription-PCR demonstrated the presence of HLA-G5 isoform in all of the tumor samples expressing HLA-G. ELISA was performed to measure the sHLA-G in 42 malignant and 18 benign ascites supernatants. sHLA-G levels were significantly higher in malignant ascites than in benign controls (P < 0.001). We found that the area under the receiver-operating characteristic curve for sHLA-G was 0.95 for malignant versus benign ascites specimens. At 100% specificity, the highest sensitivity to detect malignant ascites was 78% (95% confidence interval, 68-88%) at a cutoff of 13 ng/ml. CONCLUSIONS: Our findings suggest that measurement of sHLA-G is a useful molecular adjunct to cytology in the differential diagnosis of malignant versus benign ascites.
Authors:
Gad Singer; Vera Rebmann; Yu-Chi Chen; Hsu-Tai Liu; Syed Z Ali; Jochen Reinsberg; Michael T McMaster; Kerstin Pfeiffer; Daniel W Chan; Eva Wardelmann; Hans Grosse-Wilde; Chih-Chien Cheng; Robert J Kurman; Ie-Ming Shih
Related Documents :
16749659 - Adnexal mass: an unusual presentation of small-bowel adenocarcinoma.
8296849 - Transvaginal ultrasonographic characterization of ovarian masses with an improved, weig...
6136429 - Frozen section biopsy of ovarian neoplasms.
16787549 - Managing ovarian masses during pregnancy.
15625159 - Risk of benign gynecologic tumors in relation to prenatal diethylstilbestrol exposure.
9641229 - Leiomyosarcomas of the small intestine misdiagnosed as ovarian masses: report of three ...
15241819 - Lobular neoplasia on core-needle biopsy--clinical significance.
25120669 - Polypoid colonic metastases from gastric stump carcinoma: a case report.
18679689 - Giant gastrinoma in a child: case report and review.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  9     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  2003 Oct 
Date Detail:
Created Date:  2003-10-13     Completed Date:  2004-05-20     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4460-4     Citation Subset:  IM    
Affiliation:
Department of Pathology, Johns Hopkins University Medical Institutions, Baltimore Maryland 21231, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Ascites / diagnosis,  metabolism*
Breast / metabolism,  pathology
Breast Neoplasms / chemistry,  diagnosis,  metabolism*
Carcinoma, Ductal / chemistry,  diagnosis,  metabolism
Case-Control Studies
Cystadenoma, Serous / chemistry,  diagnosis,  metabolism
Enzyme-Linked Immunosorbent Assay
Female
HLA Antigens / genetics,  metabolism*
Histocompatibility Antigens Class I / genetics,  metabolism*
Humans
Immunoenzyme Techniques
Neoplasm Invasiveness
Neoplasm Staging
Ovarian Neoplasms / chemistry,  diagnosis,  metabolism*
Ovary / metabolism,  pathology
Reverse Transcriptase Polymerase Chain Reaction
Tumor Markers, Biological / analysis*
Chemical
Reg. No./Substance:
0/HLA Antigens; 0/HLA-G antigen; 0/Histocompatibility Antigens Class I; 0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast...
Next Document:  Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic ...